Company intelligence / Profile preview

Bluebonnet

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Bluebonnet Bio is a San Francisco-based biotechnology company dedicated to discovering and developing next-generation small molecule therapeutics. Founded by a team of experienced drug hunters from Loxo Oncology and Eli Lilly, the company leverages a modern drug discovery platform to target high-value biological pathways. Bluebonnet Bio aims to create precision medicines for oncology and other therapeutic areas by integrating structural biology and advanced medicinal chemistry. The company is currently in the early stages of building its internal pipeline of novel drug candidates.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Bluebonnet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bluebonnet.

Explore the full profile